单位:[1]HUST,Tongji Med Coll,Tongji Hosp,Dept Urol,Wuhan 430030,Hubei,Peoples R China外科学系华中科技大学同济医学院附属同济医院泌尿外科[2]HUST,Tongji Med Coll,Tongji Hosp,Inst Urol,Wuhan 430030,Hubei,Peoples R China外科学系华中科技大学同济医学院附属同济医院泌尿外科[3]HUST,Tongji Med Coll,Tongji Hosp,Dept Pediat Surg,Wuhan 430030,Hubei,Peoples R China儿科学系华中科技大学同济医学院附属同济医院外科学系小儿外科[4]Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA[5]Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney cancer. We previously reported that CD105(+) subpopulation in human ccRCC tumors possesses tumor cell self-renewal and chemoresistance capability. In this study, we showed that CD105(+) ACHN tumor cells exhibit epithelial mesenchymal transition (EMT) phenotype with high expression of mesenchymal marker N-cadherin and low expression of epithelial marker E-cadherin. They are more motile and invasive compared to the unselected parental ACHN tumor cells. The knockdown of CD105 by RNA interference led to the downregulation of N-cadherin and the upregulation of E-cadherin and reduced motility and invasiveness of CD105(+) cells. Overexpression of stem cell factor MYC in CD105 knocked down cells increased mesenchymal markers and cell motility. However, the CD105(+) population of tumor cells does not exhibit an increase metastatic potential in vivo. Findings from this study support that CD105 plays a functional role in maintaining cancer stem cell and EMT phenotype, with MYC as a common mediator for both of these traits. Our work suggests that the ability to metastasize does not coincide with the cancer stem cell or EMT function of CD105.
基金:
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31372562, 81470935]; National Major Scientific and Technological Special Project for Significant New Drugs Development [2012ZX09303018]; Chenguang Program of Wuhan Science and Technology Bureau [2015070404010199]; National High Technology Research and Development Program 863National High Technology Research and Development Program of China [2014AA020607]
第一作者单位:[1]HUST,Tongji Med Coll,Tongji Hosp,Dept Urol,Wuhan 430030,Hubei,Peoples R China[2]HUST,Tongji Med Coll,Tongji Hosp,Inst Urol,Wuhan 430030,Hubei,Peoples R China[3]HUST,Tongji Med Coll,Tongji Hosp,Dept Pediat Surg,Wuhan 430030,Hubei,Peoples R China[4]Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
通讯作者:
通讯机构:[1]HUST,Tongji Med Coll,Tongji Hosp,Dept Urol,Wuhan 430030,Hubei,Peoples R China[2]HUST,Tongji Med Coll,Tongji Hosp,Inst Urol,Wuhan 430030,Hubei,Peoples R China[4]Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA[5]Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
推荐引用方式(GB/T 7714):
Hu Junhui,Guan Wei,Yan Libin,et al.Cancer Stem Cell Marker Endoglin (CD105) Induces Epithelial Mesenchymal Transition (EMT) but Not Metastasis in Clear Cell Renal Cell Carcinoma[J].STEM CELLS INTERNATIONAL.2019,2019:doi:10.1155/2019/9060152.
APA:
Hu, Junhui,Guan, Wei,Yan, Libin,Ye, Zhangqun,Wu, Lily&Xu, Hua.(2019).Cancer Stem Cell Marker Endoglin (CD105) Induces Epithelial Mesenchymal Transition (EMT) but Not Metastasis in Clear Cell Renal Cell Carcinoma.STEM CELLS INTERNATIONAL,2019,
MLA:
Hu, Junhui,et al."Cancer Stem Cell Marker Endoglin (CD105) Induces Epithelial Mesenchymal Transition (EMT) but Not Metastasis in Clear Cell Renal Cell Carcinoma".STEM CELLS INTERNATIONAL 2019.(2019)